Complete oversight of every chart.

Clinical oversight doesn’t scale with consultation volume. The industry standard is a manual, random review of around 5% of charts, often weeks or months later. Everything else goes unreviewed.

Rubik MD helps review 100% of charts, surfaces the cases that need human attention most, and shows why. Clinical expertise lands where it matters, and the people responsible for oversight get full visibility for the first time.

• Reviews every chart asynchronously, in the background over days, so the review can be deep enough to find what would otherwise never surface.
• Flags deviations, ambiguity, and risk: dosing outside protocol, outdated treatments, missed red flags, follow-ups that never happened.
• Cites the exact trigger on every flag: the lab value, the titration, the missed follow-up.
• Puts flagged cases in a prioritized queue where clinical leadership confirms or overrides each one, and everything gets recorded.

Named, verifiable sources. Not an AI black box; every check has a source:

• FDA-approved prescribing information (official drug labels: dosing, contraindications, warnings).
• Clinical society guidelines.
• Your own protocols: the internal documents medical leadership already uses, digested so review matches how your clinics actually work.

No. Rubik MD is read-only and assistive by design. It never touches the patient, the chart, or the live workflow; it never diagnoses, prescribes, or recommends treatment. It surfaces cases and evidence. Your clinicians own every judgment.

One periodic export of visit data (notes, labs, prescriptions). Not a live EHR project, no workflow change for treating clinicians, and we stay read-only. On many cloud ambulatory systems a practice admin can produce that export themselves. On Epic, the path depends on whether the clinic owns the instance or sits on Community Connect; we still start with a small chart package and never write back into the chart.

• Data is pseudonymized before analysis.
• Processing runs on local, private models; nothing is shared with public AI services.
• Nothing is stored beyond the analysis itself; no patient data is retained long-term.
• Engagements run under a standard Business Associate Agreement (HIPAA).

One location, one export, a small batch of charts. We show you what surfaces from an ordinary week of ordinary practice. That alone tells you everything. From there, the same export on a regular cadence, across as many locations as you want visibility into.

Days, not months. The first batch of results arrives within a week of the first export.

• Initial focus: outpatient specialty care. GLP-1 and weight-management clinics first, with hormone therapy, psychiatry, and behavioral health as fast follows.
• Broader fit: any fast-scaling or multi-location medical network whose consultation volume has outgrown manual oversight.

• Malpractice is getting more expensive, and regulators are asking scaling groups for proof that clinical oversight keeps pace with growth.
• Liability carriers already grant premium credits for weaker oversight evidence than a live, 100%-coverage review record.
• AI is spreading across clinical operations; the more it is used, the more attentive oversight the work requires. We are that oversight layer.

Different user, different moment, different job:

• Copilots assist the treating clinician, live, inside the encounter.
• Rubik MD serves the people accountable for oversight, after the encounter, across all encounters: deviations, ambiguity, and risk.

The two are complements. The more copilots produce richer documentation, the more there is to oversee.

No. CDSS is a live guardrail on the ordering screen. It fires at the prescribing clinician on one order in isolation, which is why alerts get dismissed mid-visit.

Rubik MD reviews the full chart asynchronously, across days or months and across the organization’s charts, for deviations that only show at that depth. Flags go to the people accountable for oversight (site medical director, CMO), not the busy daily prescriber, and every flag carries its source.

On our proprietary GLP-1 chart benchmark, Rubik MD reaches 99% accuracy. Clinical validation happens with design-partner data, on real charts, reviewed by the client’s own clinical leadership. That’s what the pilot is for, and why the first batch tells you everything.

No. Your data is used only to run your review. The system does improve at your specifics: each confirmed or overridden flag tunes it to your protocols, and that tuning belongs to your deployment.

We raise the floor; we don’t promise a ceiling. Today, the miss rate on the 95% of charts nobody reviews is 100%. Rubik MD screens everything, prioritizes what carries risk, and documents human review of those cases. No process, human or machine, guarantees detection. What we guarantee is systematic coverage, sourced reasoning, and a recorded resolution for everything surfaced.

• Every flag targets a deviation against a named source: a protocol, the prescribing information, or a guideline.
• Sources and reasoning arrive cleanly organized, so triage takes seconds.
• The queue is prioritized: highest-risk, highest-uncertainty cases first.
• Every confirm and override tunes the system to your protocols, so noise drops batch after batch.

• We review cases, not clinicians. No scorecards, rankings, or individual metrics.
• A surfaced case is not an accusation. Plenty of what we surface is fine; the value is that it was seen at all.
• Medicine moves faster than any practitioner can track alone. Surfacing what’s hard to keep up with is how the organization supports its clinicians.

This is visibility into what’s happening. It is not policing.

The exposure already exists; today it’s just invisible. A documented process where risks are surfaced, reviewed, and resolved is the defensible position, and it’s the evidence carriers credit and regulators ask for. What’s dangerous is a known risk that’s ignored. What’s indefensible is having no process at all.